Tissue factor pathway inhibitor-2 is a novel mitogen for vascular smooth muscle cells |
| |
Authors: | Shinoda E Yui Y Hattori R Tanaka M Inoue R Aoyama T Takimoto Y Mitsui Y Miyahara K Shizuta Y Sasayama S |
| |
Affiliation: | Third Division, Department of Internal Medicine, Kyoto University Hospital, Shogoin-Kawaracho 54, Kyoto 6068507, Japan. |
| |
Abstract: | A mitogen for growth-arrested cultured bovine aortic smooth muscle cells was purified to homogeneity from the supernatant of cultured human umbilical vein endothelial cells by heparin affinity chromatography and reverse-phase high performance liquid chromatography. This mitogen was revealed to be tissue factor pathway inhibitor-2 (TFPI-2), which is a Kunitz-type serine protease inhibitor. TFPI-2 was expressed in baby hamster kidney cells using a mammalian expression vector. Recombinant TFPI-2 (rTFPI-2) stimulated DNA synthesis and cell proliferation in a dose-dependent manner (1-500 nM). rTFPI-2 activated mitogen-activated protein kinase (MAPK) activity and stimulated early proto-oncogene c-fos mRNA expression in smooth muscle cells. MAPK, c-fos expression and the mitogenic activity were inhibited by a specific inhibitor of MAPK kinase, PD098059. Thus, the mitogenic function of rTFPI-2 is considered to be mediated through MAPK pathway. TFPI has been reported to exhibit antiproliferative action after vascular smooth muscle injury in addition to the ability to inhibit activation of the extrinsic coagulation cascade. However, structurally similar TFPI-2 was found to have a mitogenic activity for the smooth muscle cell. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|